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Introduction
• Polycystic Ovarian Syndrome (PCOS) is the leading cause of
anovulatory infertility and the most common endocrinopathy in
women of reproductive age (Rosenfield & Ehrmann, 2016)
• Currently, the first-line treatment for infertility associated with
PCOS is clomiphene citrate, which was introduced in the 1960s
(Morad & Farag, 2015). However, it has been proposed that an
aromatase inhibitor, specifically letrozole, should become the
first-line treatment for these patients due to a decreased adverse
effect profile, a lower incidence of simultaneous multiple
gestation pregnancies, and a decreased risk of congenital
abnormalities

Research Question
• In the patient with polycystic ovarian syndrome, is letrozole
compared to clomiphene citrate more effective for ovulation
induction, endometrial thickness, single follicle stimulation/single
gestation birth, pregnancy rate, and live birth rate?
• In the patient with polycystic ovarian syndrome, is letrozole
compared to clomiphene citrate safer for the mother and baby
regarding ovarian hyperstimulation syndrome, congenital
anomalies, ectopic pregnancies, and miscarriage rates?

Abstract
• PURPOSE: To determine if letrozole is an equal or better
alternative to clomiphene citrate for infertility treatment in PCOS
patients
• LITERATURE REVIEW: Letrozole was found to have higher
ovulation rates, fewer twin pregnancies/more single births, higher
pregnancy rates, and higher live birth rates compared to
clomiphene citrate. There were conflicting results for endometrial
thickness and single follicle stimulation. Neither letrozole or
clomiphene citrate was superior to the other for ovarian
hyperstimulation syndrome. There were no significant differences
between letrozole and clomiphene citrate regarding congenital
abnormalities and miscarriage rates. The results regarding ectopic
pregnancies were comparable between both groups
• CONCLUSION: The results provide information supporting
letrozole as an adequate first-line alternative to clomiphene citrate
for infertility in patients with PCOS.

Statement of the Problem
• 25% of patients with infertility are clomiphene citrate resistant
and unable to ovulate, and many are unable to conceive with
clomiphene citrate and subsequently experience clomiphene
citrate failure (Legro et al., 2014)
• Clomiphene citrate has also been associated with a limited
efficacy including a 22% live birth rate and increased risk of
multiple pregnancies (Legro et al., 2014)
• If an alternative to clomiphene citrate is available that is safer and
more effective, it should be implemented as the first-line
treatment in daily medical practice

Literature Review
Efficacy
.
• Ghahiri et al: RCT, n=101. No significant difference regarding
ovulation and pregnancy rates
• Sharief & Nafee: RCT, n=75. Letrozole: Lower number of mature
follicles (p=0.0001). Letrozole: Higher endometrial thickness
(p=0.0001). Letrozole: Higher ovulation rate (p=0.05). No
significant difference in pregnancy rates
• Hussain et al: RCT, n=150. Letrozole: Higher ovulation rate
(p=0.001). Letrozole: Higher single follicle ovulation (p=0.0270).
Letrozole: Greater endometrial thickness (p=0.031). No
significant difference regarding pregnancy rate
• Legro: RCT, n=750. Letrozole: Higher cumulative live birth rate
(p=0.007). Letrozole: Higher ovulation rate (p<0.001). Letrozole:
Greater single pregnancy rate (p=0.03)
• Liu et al: RCT, n=268. No significant difference regarding
pregnancy
and
live
birth
rate.
Letrozole
treatment
group:
Higher
.
ovulation rate (p<0.001)
• Amer et al: RCT, n=159. Letrozole: Higher pregnancy rate
(p=0.022). Letrozole: Higher rate of ovulation and pregnancies
per cycle (p=0.045, p=0.035, respectively). Clomiphene citrate:
Greater endometrial thickness (p=0.002)
• Al-Shaikh: prospective clinical trial, n=85. Letrozole: Higher
number of mature follicles (p<0.05). Clomiphene citrate: Higher
endometrial thickness (p<0.05). No significant difference in
pregnancy rates per cycle
Safety
• Sharma et al: n=201. No significant difference in rate of
congenital or chromosomal abnormalities compared to natural
conception
• Legro et al: n=750. No significant difference in congenital
defects, pregnancy loss, or miscarriage rate. Letrozole: Lower
neonatal death rate and fetal death rate (p<0.05)
• Liu et al: n=63. No congenital abnormalities in either group
• Ghahiri et al: n=101. Five miscarriages in both groups. No cases
of ovarian hyperstimulation syndrome (OHSS)

Discussion
• Ovulation rate: Ghahiri et al. (2016) and Amer et al. (2017) found no
significant difference, while Sharief & Nafee (2015), Hussain et al.
(2013), Legro et al. (2014) and Liu et al. (2017) all found letrozole to
have statistically significant higher ovulation rates
• Endometrial thickness: Sharief & Nafee (2015) and Hussain et al.
(2013) found that letrozole had significantly higher endometrial
thickness, while Al-Shaikh et al. (2017) found that clomiphene citrate
had higher endometrial thickness
• Single follicle stimulation/single gestation birth: Sharief & Nafee
(2015) found that letrozole had a higher rate of single follicles, while
Al-Shaikh et al. (2017) reported letrozole to have a higher number of
single follicles. Sharief & Nafee (2015) reported one twin pregnancy
in the clomiphene citrate group/none in the letrozole group, and Legro
(2014) reported a higher single pregnancy rate with letrozole
• Pregnancy rates: Legro et al. (2014) and Amer et al. (2017) found
letrozole to have higher pregnancy rates with letrozole, other studies
found no significant difference.
• Live birth rates: Legro et al. (2014) found letrozole to have a
significantly higher live birth rate, while Liu (2017) found no
significant difference
• Ovarian Hyperstimulation Syndrome (OHSS): Ghahiri et al. (2016)
and Hussain et al. (2013) reported no cases of OHSS, while other
studies did not disclose this information
• Congenital abnormalities: No significant difference between the two
drugs (Sharma et al, [2014], Legro et al. [2014, Amer et al. [2017],
and Liu et al. [2017])
• Ectopic pregnancies: rates between the studies ranged from 2%-10.3%
in the letrozole group and 0.0%-12.5% in the clomiphene group
• Miscarriage rates: No significant findings other than Tatsumi et al.
(2017) reporting a much lower miscarriage rate with letrozole
compared to normal pregnancy

Applicability to Clinical Practice
• It is apparent that letrozole could be at the very least an equal
alternative, with more research pointing towards an improvement in
efficacy with letrozole compared to clomiphene citrate.
• Infertility due to PCOS is a very common complaint and a struggle
that is frequently brought to the provider's attention. Many women
have tried to become pregnant with other fertility treatments to no
avail or are beginning their infertility treatment journey. It is
promising that with this research and ongoing research, letrozole
will become a first-line pharmacological treatment for infertility in
PCOS patients. Providers will be able to inform their patients of all
treatment options available including letrozole and the positive
impact it can have on infertility.
• With a lower rate of multiple gestation pregnancies and a higher rate
of ovulation, pregnancy, and live birth rates, women with infertility
will be able to have more hope in their dreams of becoming a
mother with the most effective medication available to them. This
could change the provider's way of practice if the provider is able to
offer the patient an alternative medication that is superior to the
traditional option, and ultimately providing the best outcome
possible for each patient.
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